Workflow
上海复星医药(集团)股份有限公司2026年第一次临时股东会、2026年第一次A股类别股东会及2026年第一次H股类别股东会决议公告
Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where a significant resolution regarding the spin-off of its subsidiary, Fosun Antigen, was discussed. The proposal to provide guaranteed allocations to A-shareholders was rejected, but the spin-off plan remains unaffected [2][10]. Meeting Details - The extraordinary general meeting was held on February 27, 2026, at Shanghai Tianxi Jiafu Puti Hotel [3]. - The total number of shares with voting rights was 2,639,554,073, including 2,098,582,573 A-shares and 540,971,500 H-shares [3]. Voting Results - The proposal to spin off Fosun Antigen to the Hong Kong Stock Exchange was approved in the general meeting, while the specific proposal to provide guaranteed allocations to A-shareholders was not approved in the A-share meeting [7][9]. - The resolutions regarding the spin-off were passed in the H-share meeting, indicating a split in shareholder support between A and H shareholders [10]. Legal Compliance - The meeting was conducted in accordance with the Company Law of the People's Republic of China and the company's articles of association, ensuring the legality of the proceedings and voting [4][11].
上海仁度生物科技股份有限公司2025年度业绩快报公告
Financial Performance Summary - In the fiscal year 2025, the company reported operating revenue of 162.06 million RMB, a decrease of 8.62% year-on-year [4] - The net profit attributable to the parent company was 9.51 million RMB, an increase of 17.32 million RMB compared to the previous year [4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -12.28 million RMB, an increase of 7.28 million RMB year-on-year [4] - Total assets at the end of the reporting period were 989.51 million RMB, a decrease of 0.49% from the beginning of the period [4] - Equity attributable to the parent company was 913.33 million RMB, an increase of 0.16% from the beginning of the period [4] Factors Influencing Performance - The company implemented a "quality improvement and efficiency enhancement" action plan, focusing on cost reduction and expense control, which led to a year-on-year decrease in period expenses [5] - Enhanced management of receivables allowed the company to recover some receivables from previous years, resulting in the reversal of some impairment losses according to accounting standards [5] Significant Changes in Financial Metrics - The operating profit, total profit, net profit attributable to the parent company, and net profit after deducting non-recurring gains and losses increased by 24.33 million RMB, 24.76 million RMB, 17.32 million RMB, and 7.28 million RMB respectively compared to the previous year, primarily due to the factors mentioned above [6]
杰华特微电子股份有限公司2025年年度业绩快报公告
证券代码:688141 证券简称:杰华特 公告编号:2026-006 二、经营业绩和财务状况情况说明 (一)报告期的经营情况、财务状况及影响经营业绩的主要因素 杰华特微电子股份有限公司 2025年年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据,未经会计师事务所审计,具体数据以杰华特微电子 股份有限公司(以下简称"公司")2025年年度报告为准,提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位:人民币元 ■ 注:1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填制,但未经审计,最终结果以公司2025年年度报告为准。 3.以上增减变动幅度数据如有尾差,系四舍五入所致。 三、风险提示 1、经营情况及财务状况 报告期内,公司实现营业总收入265,870.23万元,同比增长58.37%;实现归属于母公司所有者的净利 润-71,657.88万元,归属于母公司所有者的扣除非经常性损益的净利润-80,264.95万元。 报告 ...
无锡力芯微电子股份有限公司2025年年度业绩快报公告
Core Viewpoint - The company reported a decline in key financial metrics for the year 2025, indicating challenges in market demand and increased competition, despite some growth in sales volume [2][3]. Financial Performance and Indicators - The company achieved an operating income of 76,847.49 million RMB, a decrease of 2.42% compared to the previous year [2]. - Operating profit was 1,317.19 million RMB, down 89.94% year-on-year [2]. - Total profit amounted to 1,208.20 million RMB, reflecting a decline of 90.69% from the previous year [2]. - Net profit attributable to shareholders was 3,571.37 million RMB, a decrease of 71.62% compared to the previous year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1,650.07 million RMB, down 84.28% year-on-year [2]. - Total assets at the end of the reporting period were 146,512.93 million RMB, an increase of 0.52% from the beginning of the period [2]. - Equity attributable to shareholders was 124,773.35 million RMB, a decrease of 1.38% from the beginning of the period [2]. - Basic earnings per share decreased, with net assets per share at 9.40 RMB, down 1.36% from the beginning of the period [2]. Factors Affecting Performance - The decline in operating performance was primarily due to weak external market demand, fluctuations in supply chain costs, and intensified industry competition [3][4]. - Although sales volume increased, the gross profit margin decreased compared to the previous year, leading to a slight decline in operating income [3]. - The company significantly increased its R&D expenses to enhance its technology reserve and product matrix, which, while beneficial in the long term, exerted short-term pressure on profit levels [3]. - The expansion of the sales team to strengthen market penetration and brand promotion resulted in increased sales expenses [3].
杭州奥泰生物技术股份有限公司2025年度业绩快报公告
Core Viewpoint - The company reported a total revenue of 911.30 million RMB for the year 2025, reflecting a growth of 5.16% compared to the previous year, but net profit decreased by 27.83% due to various cost pressures and increased expenses [2][3]. Financial Performance and Condition - The company achieved total revenue of 911.30 million RMB, a 5.16% increase year-on-year - Net profit attributable to shareholders was 218.28 million RMB, down 27.83% from the previous year - Net profit excluding non-recurring gains and losses was 155.25 million RMB, a decline of 34.64% compared to the previous year - Total assets at the end of the reporting period were 4,248.62 million RMB, up 1.50% from the beginning of the period - Shareholders' equity attributable to the parent company was 3,944.50 million RMB, an increase of 1.57% from the beginning of the period [2]. Factors Affecting Performance - The company maintained competitive advantages in R&D innovation, product quality, and customer service, which helped to expand sales channels and increase customer sales volume - Increased investment in new technology platforms and efforts in domestic and international market registrations led to higher R&D and sales costs - Additional factors impacting profit included increased operating costs due to U.S. tariffs, foreign exchange losses from currency fluctuations, reduced interest income, and increased asset depreciation [2][3]. Significant Changes in Financial Metrics - Despite a revenue increase of 5.16%, the overall profitability was pressured by declining product prices, rising sales, management, and R&D expenses, as well as increased financial costs - Key financial metrics such as operating profit, total profit, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses all saw declines of 27.72%, 28.36%, 27.83%, and 34.64% respectively compared to the previous year [3].
北京格灵深瞳信息技术股份有限公司2025年度业绩快报公告
2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据,未经会计师事务所审计,具体数据以公司2025年年 度的定期报告为准,提请投资者注意投资风险。 证券代码:688207 证券简称:格灵深瞳 公告编号:2026-004 北京格灵深瞳信息技术股份有限公司 一、2025年度主要财务数据和指标 单位:人民币万元 ■ 注:1.本报告期初数同法定披露的上年年末数。 2.以上增减变动幅度数据如有尾差,是由于四舍五入所造成。 3.上表中"基本每股收益"的普通股股数为总股本扣除报告期内回购股份的加权平均数;"归属于母公司 所有者的每股净资产"中期末普通股股数为总股本扣除回购股份数。 4.以上财务数据及指标以合并报表数据填列,但未经审计,最终结果以公司2025年年度报告为准。 二、经营业绩和财务状况情况说明 (一)报告期的经营情况、财务状况及影响经营业绩的主要因素 1、报告期的经营情况、财务状况 2026年2月28日 2025年度,公司实现营业总收入15,545.11万元 ...
精进电动科技股份有限公司2025年度业绩快报公告
证券代码:688280 证券简称:精进电动 公告编号:2026-007 精进电动科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载精进电动科技股份有限公司(以下简称"公司")2025年度主要财务数据为初步核算数据,未 经会计师事务所审计,具体数据以公司2025年年度的定期报告为准,提请投资者注意投资风险。 一、2025年度主要财务数据和指标 ■ 注:1.本报告期初数同法定披露的上年年末数。 2.编制合并报表的公司应当以合并报表数据填制,但未经审计,最终结果以公司2025年年度报告为准。 3.数据尾差为四舍五入所致。 二、经营业绩和财务状况情况说明 (一)报告期的经营情况、财务状况及影响经营业绩的主要因素 1、经营状况 单位:万元,币种:人民币 报告期内,公司营业总收入272,632.61万元,较上年同期增长108.93%。公司预计实现归属于母公司所 有者的净利润16,174.54万元,较上年同期增长137.06%;预计实现归属于母公司所有者的扣除非经常性 损益的净利润4, ...
宁波均普智能制造股份有限公司2026年第一次临时股东会决议公告
2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示: 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:688306 证券简称:均普智能 公告编号:2026-022 宁波均普智能制造股份有限公司 ● 本次会议是否有被否决议案:无 一、会议召开和出席情况 (一)股东会召开的时间:2026年2月27日 (二)股东会召开的地点:浙江省宁波市高新区清逸路99号4号楼 (三)出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况: ■ (四)表决方式是否符合《公司法》及公司章程的规定,股东会主持情况等。 本次会议由公司董事会召集,现场会议由公司董事长王剑峰先生主持。会议采用现场投票和网络投票相 结合的表决方式。本次会议的召集、召开及表决方式均符合《公司法》、《上海证券交易所科创板股票 上市规则》、《上市公司股东会规则》、《公司章程》及《公司股东会议事规则》等有关规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事9人,列席9人。 2、董事 ...
上海合晶硅材料股份有限公司2025年度业绩快报公告
证券代码:688584 证券简称:上海合晶 公告编号:2026-003 上海合晶硅材料股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 2.以上财务数据及指标以合并报表数据填列,但未经审计,最终结果以公司2025年年度报告为准。 本公告所载2025年度主要财务数据为初步核算数据,未经会计师事务所审计,具体数据以上海合晶硅材 料股份有限公司(以下简称"公司")2025年年度报告为准,提请投资者注意投资风险。 一、2025年度主要财务数据和指标 二、经营业绩和财务状况情况说明 (一)报告期的经营情况、财务状况及影响经营业绩的主要因素 报告期内,全球半导体市场复苏迹象显著,公司下游功率器件以及模拟芯片市场也逐步回暖,带动外延 片需求增长,下游客户库存水位回归合理,产品销量增加,产能利用率维持高位,带动收入和净利润的 上升。公司2025年实现营业总收入131,134.18万元,同比增长18.27%;实现归属于母公司所有者的净利 润12,534.97万元,同比增长3.78%;归属于母公司所有者的 ...
北京龙软科技股份有限公司关于使用剩余超募资金永久补充流动资金的公告
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:688078 证券简称:龙软科技 公告编号:2026-004 根据中国证券监督管理委员会《关于同意北京龙软科技股份有限公司首次公开发行股票注册的批复》 (证监许可[2019]2575号)的批准,公司获准向社会公开发行人民币普通股1,769万股,每股面值为1.00 元,每股发行价格为21.59元,公司收到募集资金总额为381,927,100.00元,扣除发行费用后募集资金净 额为323,631,025.28元。上述募集资金已于2019年12月24日全部到位,瑞华会计师事务所(特殊普通合 伙)于2019年12月24日出具了"瑞华验字[2019]02290001号"《验资报告》。募集资金到账后,已全部存 放于经公司董事会批准开设的募集资金专项账户内,公司与保荐机构、存放募集资金的商业银行签署了 《募集资金专户存储三方监管协议》,保证募集资金监管的有效实施,同时严格按照相关法律法规和规 范性文件的要求及时履行信息披露义务。 二、募集资金的使用情况 公司本次募集资金主要用于以下项目: 单位:万元 北京龙软科技股份有限公司 关于使用剩余超募资金永久补充流动资金的 ...